Pancreatic Cells TRIZ Cases

Microporous 3D scaffolds create uniform insulin-producing cell clusters, improving differentiation reliability while reducing cell loss.

DNA replication inhibitors drive cell cycle exit to produce stable, pure pancreatic endocrine cells with lower teratoma risk.

ENTPD3-based live sorting isolates mature stem cell-derived β-cells, improving insulin secretion and reducing cells needed for therapy.

Exogenous collagen I homotrimers help primary tumor tissues form viable 3D organoids that better mimic in vivo conditions over extended culture.

Human islet-on-chip co-culture with vascular endothelium improves insulin secretion and makes Type 2 diabetes drug screening more predictive.

A hydrogel patch graft places donor cells directly on solid organs to avoid emboli, limit ectopic delivery, and improve engraftment.

Reduced MHC expression with elevated CD47 helps allogeneic cells evade host immune attack and persist longer in cell therapies.

A short posterior foregut culture window improves β-cell yield, purity, and reproducibility while reducing unwanted cell types.

Single-cell endocrine progenitors form 3D aggregates to improve β-cell yield, reproducibility, and purity while limiting unwanted cell types.

A staged growth-factor protocol drives pluripotent cells toward glucose-responsive, single-hormone insulin-positive beta cells.

CRISPR-edited beta-like cells block key immune targets to resist autoimmune killing while preserving insulin secretion in type 1 diabetes.

Targeted aspartate, glycine, and serine supplementation boosts NKX6.1-positive pancreatic islet cell differentiation for transplantation.